Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Int J Gynaecol Obstet ; 163(1): 96-102, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37183712

RESUMEN

OBJECTIVE: To assess the associations between depot medroxyprogesterone acetate (DMPA) and endometrial cancer. METHODS: This multicenter case-control study was conducted among tertiary hospitals in Thailand. Patients were women with endometrial cancer. Controls were women admitted for other conditions, matched for age within 5 years of the patients' age. The controls had to have no abnormal vaginal bleeding, history of hysterectomy, or cancers of the other organs. A standardized questionnaire was used to gather information. Conditional logistic regression was applied to calculate adjusted odds ratio (aORs) and 95% confidence intervals (CIs). RESULTS: During 2015 to 2021, 378 patients and 1134 controls were included. Ever use of DMPA was associated with a 70% decreased overall risk of endometrial cancer (aOR, 0.30 [95% CI, 0.21-0.42]). Endometrial cancer risk declined by 3% (aOR, 0.97 [95% CI, 0.96-0.98]) for every 3 months of DMPA use. The magnitude of the decline in endometrial cancer risk did not vary appreciably by cancer subtypes (aOR, 0.26 [95% CI, 0.17-0.41] and 0.38 [95% CI, 0.22-0.65] for low-grade and high-grade tumors, respectively). CONCLUSIONS: Depot medroxyprogesterone acetate use was inversely associated with endometrial cancer risk in a duration-dependent manner. This association was independent of cancer subtype.


Asunto(s)
Anticonceptivos Femeninos , Neoplasias Endometriales , Humanos , Femenino , Preescolar , Masculino , Acetato de Medroxiprogesterona/efectos adversos , Estudios de Casos y Controles , Neoplasias Endometriales/inducido químicamente , Neoplasias Endometriales/epidemiología , Anticonceptivos Femeninos/efectos adversos , Endometrio , Preparaciones de Acción Retardada
2.
Int J Gynaecol Obstet ; 124(2): 160-3, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24139474

RESUMEN

OBJECTIVE: To assess postcolposcopy compliance among women with abnormal cervical screening results and to identify factors associated with noncompliance for postcolposcopy follow-up. METHODS: In a retrospective study, the records of women who underwent colposcopy at Srinagarind Hospital, Thailand, between January and December 2010 were reviewed. Women were considered to be noncompliant if their total follow-up time after colposcopy was less than 12months. Univariate and multivariate logistic regression methods were used to determine factors significantly predicting noncompliance. RESULTS: Among 548 women who underwent colposcopy, the percentage of noncompliance was 49.5% (95% confidence interval [CI], 45.1%-53.7%). The risk for noncompliance rose significantly among those without intraepithelial lesions (OR, 2.19; 95% CI, 1.53-3.13), younger age (OR, 1.79; 95% CI, 1.19-2.67), and low education level (OR, 1.58; 95% CI, 1.11-2.24). Risk for noncompliance was significantly lower among those with a previous history of abnormal smear (OR, 0.39; 95% CI, 0.24-0.64). CONCLUSION: The percentage of noncompliance with postcolposcopy follow-up was high among the study women. The significant independent factors predicting noncompliance were previous history of abnormal smear, severity of cervical histopathology, age, and education level.


Asunto(s)
Detección Precoz del Cáncer , Cooperación del Paciente , Displasia del Cuello del Útero/patología , Neoplasias del Cuello Uterino/patología , Frotis Vaginal , Adulto , Factores de Edad , Colposcopía , Escolaridad , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Persona de Mediana Edad , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA